Healing Peptides (BPC-157 / TB-500): When to Pick Which Agent
HealthRX.com
No human data supports picking TB-500 over BPC-157
At a glance
- TB-500 approval status / Not FDA-approved; no approved product in the US, EU, UK, Canada or Australia [1]
- Approved TB-500 dose / None; no human dosing study [1]
- BPC-157 injury evidence / One 16-patient retrospective chart review, no control group [2]
- Combined use in people / 4 chart-review patients received BPC-157 with a thymosin beta-4 product of unspecified form [2]
- Combined-product report / Skin and gum darkening; FDA could not attribute it to either peptide [4]
- Sport / WADA prohibits thymosin-beta-4 and its derivatives including TB-500 at all times [5]
- FDA compounding view / Staff proposed against listing TB-500; the July 2026 committee vote is non-binding advice [1][6]
What are the two molecules?
BPC-157 is a 15-amino-acid peptide (GEPPPGKPADDAGLV) tested mainly in rat injury models [7]. TB-500 is a much smaller molecule: the N-acetylated 7-amino-acid fragment (residues 17 to 23, about 889 g/mol) of the 43-amino-acid protein thymosin beta-4. It is not full-length thymosin beta-4 and not thymosin alpha-1, and FDA found several salts and derivatives with different active moieties sold under the same name [1].
What evidence exists, and do the thymosin beta-4 trials apply?
The human injury data are small and uncontrolled. A retrospective chart review at one Florida clinic reached 16 people by phone after intra-articular peptide injections: 12 had BPC-157 alone and 4 had BPC-157 plus a thymosin beta-4 product of unspecified form. Three of the 4 reported significant improvement, against 11 of 12 on BPC-157 alone; there was no control group, no validated tool and results were recalled [2]. A 2013 review also mentions BPC-157 clinical trials in inflammatory bowel disease and wound healing without giving enough detail to assess them [3]; in rats, the peptide improved healing of transected medial collateral ligaments [7]. For TB-500, an in-vitro scratch-wound test at 50 micrograms/mL did not induce wound closure in fibroblast cultures [1].
Trials of full-length thymosin beta-4 do not answer the question, because they tested a different molecule. In one phase 1 study, 54 volunteers were assigned to single intravenous-dose cohorts receiving the recombinant protein or placebo, and 30 were enrolled in multiple-dose cohorts; adverse events were mild to moderate, with no dose-limiting toxicity or serious adverse events [8]. Eye-drop and post-heart-attack trials used the same full-length molecule [9][10].
What people on Reddit report
Reddit users in one thread comparing two healing peptides for recovery. They describe using one, the other, or both together, and they disagree about whether injecting near the injury matters.
My opinion, BPC is the project designer and manager. TB is the crew. They work best together. Synergy.Read the source discussion
TB4 is good for soft tissue injuries, but they're both good for healing.Read the source discussion
Well BPC doesn't work locally. It works systemically. You inject it and the body tells the healing properties where to go to.Read the source discussion
Questions worth asking
What happens when the two are combined?
A knee-pain chart review included four people who received BPC-157 with thymosin beta-4 of unspecified form [2]. Separately, FDA described a 40-year-old woman who injected a research-purposes-only BPC-157 plus TB-500 (5 mg/5 mg) product subcutaneously twice daily and developed widespread skin hyperpigmentation and gum darkening within a week, recurring when she re-tried it two weeks later; with two peptides in the product, FDA could not tell which one caused it [4].
What is the regulatory and sport position?
TB-500 sits in the nominated-but-withdrawn table of FDA's safety-risk page, not the active category 2 table, and removal from that category was not a safety finding [11]. FDA staff proposed in July 2026 that neither TB-500 free base nor acetate be added to the compounding bulks list, citing no human data and immunogenicity risk [1], while the Pharmacy Compounding Advisory Committee voted in favour on July 23, 2026, which is advice only [6]. A draft HHS policy filed October 28, 2026 names TB-500 among six peptides, covers the acetate form by injection, and says HHS does not intend to take enforcement action against certain pharmacies and physicians if its conditions, including a single active ingredient, are met; it is not an approval [12][13]. WADA lists 'Thymosin-beta4 and its derivatives e.g. TB-500' in S2.3, prohibited at all times [5][14].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Frequently asked questions
Is TB-500 the same as thymosin beta-4?
Can BPC-157 and TB-500 be used together?
What dose of TB-500 is used?
Is TB-500 banned in sport?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
How often should I take BPC-157 and TB 500?
No established schedule is given. TB-500 has no approved dose and no human dosing study. The only frequency mentioned is a research-purposes-only BPC-157 plus TB-500 product (5 mg/5 mg) injected twice daily by one woman, whom FDA described as developing widespread skin hyperpigmentation and gum darkening within a week.
Is TB 500 the same as BPC-157?
No. BPC-157 is a 15-amino-acid peptide (GEPPPGKPADDAGLV) tested mainly in rat injury models. TB-500 is a much smaller N-acetylated 7-amino-acid fragment (residues 17 to 23) of the 43-amino-acid protein thymosin beta-4. FDA found several salts and derivatives sold under the same name.
References
Show all 15 referencesHide references
- U.S. Food and Drug Administration.
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13.
- Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, et al. Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157. Curr Pharm Des. 2013;19(1):76-83.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- U.S. Food and Drug Administration.
- Cerovecki T, Bojanic I, Brcic L, Radic B, Vukoja I, Seiwerth S, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155-61.
- Wang X, Liu L, Qi L, Lei C, Li P, Wang Y, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med. 2021;25(17):8222-8228.
- Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. Clin Ophthalmol. 2015;9:877-84.
- Zhang Y, Dong Q, Bian X, Qiao Z, Cui C, Yang N, et al. Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion. Cardiovasc Res. 2025;121(17):2747-2758.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- Official web page.
- Official web page.
- World Anti-Doping Agency.
- Reddit participants. BPC-157 vs TB-500: Which One Works Better for Recovery? (r/NTNPerformance). Accessed 2026-11-10.